|
Outcomes of treatment efficacy
| |
|
Aggression*
| |
|
Agitation
| |
|
Depression
| |
|
Apathy
| |
|
Anxiety
| |
|
Night-time behaviors
| |
|
Motor disturbances
| |
|
Irritability
| |
|
Disinhibition
| |
|
Psychosis (delusions and hallucinations)
| |
|
Appetite and eating abnormalities
| |
|
Caregiver well-being
| |
|
Overall quality of life (both patient and caregiver)
| |
|
Improvement in function
| |
|
Admission to skilled nursing facility
| |
|
Outcomes of treatment safety
| |
|
Fractures*
| |
|
Falls
| |
|
Stroke
| |
|
Mortality
| |
|
Prolonged QTc interval
| |
|
Myocardial infarction
| |
|
Pneumonia
| |
|
Deterioration in cognition
| |
|
Hyperprolactinemia
| |
|
Weight gain
| |
|
Somnolence
| |
|
Hypotension
| |
|
Edema
| |
|
Cytopenia
| |
|
Extrapyramidal side effects (e.g., tardive dyskinesia)
| |
|
Hospitalization
| |
|
Admission to intensive care unit (ICU)
| |
